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ABSTRACT 
 
Introduction Optimal management of soft tissue sarcoma (STS) remains a challenge. A 
nationwide survey assessed the quality of STS care in the Netherlands, thereby aiming to 
identify potentialities for improvement through more centralized disease management. 
Methods From the Netherlands Cancer Registry (NCR), data were obtained on 3,317 adult 
STS patients (excluding gastrointestinal stromal tumor, GIST) diagnosed in 2006–2011. 
Logistic regression models were employed to compare outcomes on selected clinical 
indicators reflecting prevailing STS guidelines between high-volume (≥10 resections 
annually) and low-volume (<10 resections) hospitals, between academic and general 
hospitals, and between sarcoma research centers and other hospitals, adjusted for case mix. 
Analyses were performed on imputed datasets (m=50), generated through multiple 
imputations by chained equations. 
Results Overall, 89% of patients underwent surgical resection. Resection status remained 
unknown in 24% (excluding those with metastasized disease), and grade was not documented 
for one-third of tumors. Microscopic residual disease was detected in 20% with an increased 
risk for older patients, larger and deeply located tumors and those located in the 
(retro)peritoneum or upper extremity. Almost half of patients with an R1 resection received 
adjuvant radiotherapy. Following adjustment for case mix factors, patients treated in high-
volume hospitals less often had macroscopic residual disease (R2 resection; adjusted odds 
ratio: 0.54). A strongly skewed distribution of surgical volumes was observed. 
Conclusion These survey results indicate a potential for improving Dutch STS care. More 
centralized sarcoma management should improve definitive pathology reporting on tumor 
characteristics, adherence to treatment guidelines and overall disease outcome. 
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INTRODUCTION 
 
Soft tissue sarcomas (STS) form a heterogeneous group of tumors deriving from 
mesenchymal progenitor cells, often showing differentiation towards different mesenchymal 
cells (e.g. fibrous tissue, adipose tissue, smooth and striated muscle). The etiology remains 
unknown. They account for 1% of all malignant tumors, incidence rates increase with age 
and show a slight male predominance. (1, 2) 
STS are primarily defined by the local aggressive growth pattern and categorized in more 
than 50 histological subtypes.(3, 4) Tumor entities vary substantially in biological behavior 
and tumor grade indicate tendency for distant metastasis, mainly to the lungs.(5, 6) 
Approximately 25% of STS patients develop distant metastases (7)
 
whereas lymphogenic 
spread is very rare, affecting only 2-3% of all STS patients.(8, 9) Besides STS subtype and 
grade, studies have identified anatomic site, tumor stage, size and depth as predictors for 
survival.(10) These parameters are included in several nomograms to estimate prognosis 
regarding local recurrence and survival.(11) Hence, obtaining accurate information on these 
factors is crucial for formulating a multidisciplinary treatment plan.
  
The diverse presentation and localization of STS contribute to the challenges for optimal 
patient care. Timely diagnosis, for instance, may be difficult given the benign to malignant 
ratio of soft tissue tumors that has been estimated at a 100 to one. Furthermore, because of 
their rarity, physicians seldom encounter STS patients in their practice. Even if recognized as 
such, the complexities in the diagnostic work-up and treatment of STS require adequate 
expertise and organization.(7) 
Studies have emphasized the importance of guideline adherence in STS care as it results in 
better patient outcomes.(12-14) In the Netherlands, national sarcoma guidelines were 
established in 1993, with updates in 2003 and 2011.(15) Key recommendations (which 
became affirmed after our study period through the international guidelines issued by the 
European Society for Medical Oncology, ESMO)(16, 17) concerned the adequate pathology 
reporting of the main prognostic sarcoma characteristics, complete diagnostic work-up of 
large (>5 cm), deeply located STS (imaging supplemented with pathologic examination) and 
the use of adjuvant radiotherapy after R1 resection (microscopic residual disease) or tumor 
spill.(18)
 
The purpose of this nationwide survey was acquiring insight in the performance of hospitals 
on STS care (excluding gastrointestinal stromal tumor, GIST), thereby identifying reference 
points for furthering quality of sarcoma care. In addition the potential improvement due to 
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centralization of STS care was explored by comparing performance between high and low-
volume hospitals, academic centers versus general hospitals and sarcoma research centers 
versus other hospitals.  
 
PATIENTS AND METHODS 
 
Database 
The Netherlands Cancer Registry (NCR) founded in 1989 includes all newly diagnosed 
malignancies, currently covering 17 million inhabitants. The main source of notification is 
the nationwide network and registry of histo- and cytopathology (www.palga.nl) and case 
ascertainment was achieved by linkage with the central hospital discharge registry. Upon 
notification, registrars gather data on patient and tumor characteristics and primary treatment 
modalities by extracting information directly from the hospital files. The NCR reports on 
national cancer incidence, prevalence, survival and mortality (www.cijfersoverkanker.nl). 
Consent for the design, data abstraction process as well as storage protocols for this study 
was obtained from the supervisory committee of the NCR. 
NCR data include patients’ age at diagnosis, histological subtype of sarcoma on the basis of 
the World Health Organization (WHO) classification 2002,(19) and tumors’ grade according 
to the grading system of the French Federation of Cancer Centers (FNCLCC) Sarcoma 
Group.(4) Primary sites are translated to ICD-O topography codes(20) and tumor stage (depth 
and size) is recorded according to the TNM system of the International Union Against Cancer 
(UICC) (21, 22) supplemented with the Extent of Disease code of the American Surveillance, 
Epidemiology and End Results (SEER) program if available.(23) Therapy is coded in 
sequence of administration, with codes differentiating between treatment modalities (surgery, 
radiotherapy, systemic therapy). In case of surgical treatment, date of resection and residual 
disease status are recorded.  
For this study data were retrieved on adult STS patients (≥18 years) diagnosed during the 
period 2006–2011, excluding Kaposi sarcoma, GIST and sarcoma of the skin (Supplementary 
Table 1). Hospitals performing sarcoma surgery were classified according to their mean 
annual number of resections over the total study period as either high-volume (≥10 
resections) or low-volume (<10 resections) and in addition hospital type (general versus 
academic hospitals) and sarcoma research centers versus other hospitals. Research centers 
were characterized by participation in the European Organization for Research and Treatment 
of Cancer (EORTC) sarcoma group, which amongst others implies expertise of dedicated 
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multidisciplinary sarcoma teams and centralized pathology review. These centers are 
Netherlands Cancer Institute Amsterdam, University Medical Center Rotterdam, University 
Medical Center Groningen, University Medical Center Nijmegen and University Medical 
Center Leiden. 
 
Clinical indicators 
Guideline adherence was evaluated with indicators reflecting quality of STS care and for 
which data were available in the NCR. The quality of pathology reports was determined by 
the availability of information on sarcoma subtype, grade, and assessment of residual disease 
status after surgery.(24) In assessing the reports on grading, we excluded sarcoma subtypes 
that are not graded by definition or for which grading was not recommended: MPNST, 
angiosarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell 
sarcoma and epithelioid sarcoma.(19) Histomorphological codes M8800–M8806 were 
considered sarcoma lacking specific subtyping, and the availability of grade was assessed 
separately in the subgroup of liposarcoma (excluding well-differentiated tumors), 
fibrosarcoma, and leiomyosarcoma. In rating adequate reporting of residual disease, M1 
disease and retroperitoneal tumors were excluded from the analyses.  
The quality of the diagnostic workup of STS was evaluated by estimating the proportion of 
possible ‘whoops’ resections. Although the NCR data did not distinguish between planned 
and unplanned procedures, potentially unplanned procedures were defined as resections of 
either large (>5 cm) or deep tumors (located beneath the superficial fascia, or with invasion 
of or through the fascia) without prior histopathologic information. In these cases, the date of 
first histopathologic confirmation coincided with the date of surgery. 
In evaluating the use of adjuvant therapy, analysis was focused on the proportion of patients 
receiving radiation therapy. In particular, the prevalent guidelines recommend provision of 
adjuvant radiotherapy to patients with R1 resections, irrespective of their tumors’ grade. For 
the evaluation of adjuvant treatment, cases with distant disease and retroperitoneal tumors 
were excluded. 
In addition overall 5-year survival rates in high-grade, non-metastasized tumors in surgical 
resected patients was estimated. 
 
Statistical analyses 
Resection rates and rates of R1 resections were tabulated by subgroups of patient and STS 
characteristics, and differences for significance were tested by χ2 tests. Potential prognostic 
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factors for R1 resections were selected for evaluation in multivariable logistic regression on 
the basis of p-value <0.1 in the univariable analyses. Odds ratios were calculated together 
with 95% likelihood ratio confidence intervals. 
Performances on most clinical indicators were analyzed as binary variables and logistic 
regressions were again applied to estimate the impact of hospital types on management of 
STS patients. Overall survival rates and hazard ratios were estimated in proportional hazards 
models. To account for missing data, multiple imputation was performed by chained 
equations under the assumption of missingness being random, thereby creating 50 data sets 
for each estimation. In addition to crude pooled estimates, we also provided odds and hazard 
ratios based on the imputed data adjusted for relevant case mix factors. All tests were two-
sided and p-values <0.05 were considered statistically significant. Statistical analyses were 
performed using Stata (version 14.0; StataCorp, College Station, Texas). 
 
RESULTS 
 
Patient and tumor characteristics 
In total 3,317 patients, 1,830 men (55%) and 1,487 women (45%) were diagnosed with a 
primary STS (Table 1). The median age was 63 (interquartile range 50–75) years; 47% was 
>65 years. Tumors were mostly located in the extremities (47%), e.g. lower extremity (34%) 
and upper extremity (13%), followed by the trunk (36%), head and neck region (11%) and 
retroperitoneum (7%). The majority of tumors were high-grade (54%). In over a quarter of 
cases (28%), no information on grade could be retrieved from the pathology report. Almost 
one-third of STS (32%) was considered small (<5 cm), 61% larger than 5 cm and in 7% the 
tumor size could not be retrieved from the clinical or pathology report. Superficially and 
deeply located tumors were approximately evenly distributed (46% and 43%, respectively), 
while depth was not reported in 12%. Metastatic disease was encountered in 14%. 
Liposarcoma (20%) and leiomyosarcoma (21%) comprised the most prevalent histology 
(Table 2). 
Most patients underwent a resection (81%). Patients who did not underwent surgery were 
relatively older (median age 69 years versus 62 years), more often a tumor in the trunk (54% 
versus 32%) and less often in the extremities (26% versus 51%). Overall, resected tumors 
exhibited more favorable characteristics: lower grade, relatively smaller, more often 
superficially located and mostly localized disease. Surgery was performed in 14% of initial 
Soft tissue sarcoma care in the Netherlands 
 7 
stage IV disease. Forty percent of the 1,081 operated patients received radiation therapy, 
whereas 191 patients received chemotherapy (7%) (data not shown). 
One-fifth of the resections were R1 resections (20%), thereby excluding cases with 
macroscopic and unknown residual disease and those primarily diagnosed with distant 
disease. R1 resections occurred more often in elderly patients and with tumors located in the 
(retro)peritoneum or upper extremity, and less often in the trunk and lower extremity. In 
addition, surgery for larger STS and deeply located tumors showed an elevated risk of 
positive resection margins. Among patients who had an R1 resection, the proportion 
receiving adjuvant radiotherapy was 47%. 
 
Hospital characteristics 
During the study period, diagnostic work and resection of STS was performed in 96 hospitals. 
Among these were eight academic hospitals and one cancer center (classified in the analyses 
as academic hospital); five of these were considered sarcoma research centers. A strongly 
skewed distribution of case volumes by hospital was observed (Figure 1). Overall 12% of 
hospitals accounted for half of all STS resections; this proportion decreased from 16% in 
2006 to 10% in 2011. Furthermore, 75% of resections was performed in one-third of 
hospitals, while 90% was performed in almost two-third. Sarcoma research centers 
represented the largest surgical volume. 
Over time, no trend was detected for whether or not patients underwent surgery in high-
volume hospitals. However, we did observe a significant trend within the high-volume group: 
while the proportion of patients treated in hospitals performing a yearly total of 10–19 
resections decreased from 27% in 2006 to 2% in 2011, there was an increase for those treated 
in hospitals performing 20 or more resections annually (p=0.01; Figure 2A). Academic 
hospitals accounted for 46% of STS resections, and this proportion did not show a trend over 
time (Figure 2B). In contrast, the proportion of patients treated in sarcoma research centers 
increased from 28% to 41% (p<0.01; Figure 2C).  
 
Clinical indicators 
With respect to pathology reports, sarcoma subtype remained unknown in 20% of patients, 
tumor grade in 28% (when restricted to the subset of liposarcoma, fibrosarcoma, and 
leiomyosarcoma cases: 24%) and resection status in 24% (Table 3). High-volume pathology 
laboratories (compared to low-volume) and those located in academic hospitals (compared to 
those in general hospitals) and sarcoma research centers (compared to those in other 
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hospitals) performed better in reporting tumor grade, resection status, whereas no difference 
was observed for reporting sarcoma subtype. 
Following adjustment for case mix factors, resection rates of deep or large tumors without 
prior histopathologic confirmation seemed considerably higher in low-volume hospitals, 
general hospitals and in non-sarcoma research centers. In academic hospitals and sarcoma 
research centers, a larger proportion of operations comprised R1 resections. 
The odds for sarcoma patients to receive radiotherapy appeared higher when surgery was 
performed in high-volume hospitals, academic hospitals and sarcoma research centers. The 
same was true regarding adjuvant radiotherapy following R1 resection, although this effect 
was no longer significant between academic and general hospitals after adjustment for case 
mix factors. 
No differences in 5-year overall survival rates were detected between hospital categories. 
 
DISCUSSION 
 
This survey indicates a need for improving STS care in the Netherlands, both in acquisition 
and reporting accurate diagnostic information and providing optimal STS treatment. 
Important STS tumor characteristics remained unmentioned in one-fifth of the pathology 
reports. The diagnostic work-up of large or deeply located STS was incomplete in almost 
one-third. More than half of patients did not receive the required adjuvant radiation. This 
does not preclude, however, that patients and physicians may have opted for active 
surveillance to monitor the tumor’s biological behavior, provided that salvage surgery could 
be performed in the event of a recurrence. 
For particular indicators (grade, resection status, ‘whoops’ resection, and delivery of 
radiotherapy), outcomes were better when diagnostic and treatment occurred in either high-
volume hospitals, academic hospitals, and sarcoma research centers compared to other 
hospitals. Surgery in high-volume hospitals less often resulted in R2 resections. The 
introduction of evidence-based national STS guidelines produced little effect in contrast to 
bone sarcoma guidelines.(25) Compliance to these guidelines was mostly moderate, 
particularly in smaller hospitals.(14) Earlier surveys carried out in France and the UK also 
showed disappointing compliance rates regarding STS guidelines, with overall estimates 
approximating 50% at best,(26-29) and rates having remained fairly constant over time.(30) 
Such situations do appear to be successfully ameliorated by regional initiatives, for instance 
directed at improving the quality of pathology reports.(13) 
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To be sure, strict conformity to guidelines far from qualifies as optimal STS care. For 
instance, to preserve functionality of limbs affected by STS, positive margins may well be 
justifiable.(31) This would explain our counterintuitive finding that R1 resections more often 
occurred in academic hospitals and in sarcoma research centers: an R1 resection oftentimes 
represents the only treatment option for locally advanced STS.(32) In case of residual disease, 
irrespective of it being microscopic or macroscopic cancer, an attempt to obtain adequate 
margins through re-excision should be evaluated, and the same holds for administration of 
adjuvant multimodality therapy. As for the observed omittance of adjuvant radiotherapy 
following an R1 resection, we could not rule out that wait-and-see policies were in fact 
pursued in such cases. In addition, treatment may have been withheld for both disease and 
patient-related factors (performance status, comorbidity).(33) 
These considerations point to the limitations of this survey, the lack of information on 
patients’ performance status and comorbidities, the intent of treatment provided as well as the 
reasons for treatment omittance. As a consequence, case mix corrections may not have 
adequately accounted for the full variance of baseline characteristics across different hospital 
categories. Also, we were not able to conclusively infer from the cancer registry data whether 
resections without prior histopathologic confirmation indeed concerned unplanned excisions 
(‘whoops’ procedures). In addition, since no central pathology review was carried out, 
misdiagnosed cases may well have been included in the analyses. Nevertheless, the results 
seems largely valid for assessing STS care in the Netherlands: the analyses were performed 
on an unselected sample of Dutch STS patients, and main outcomes are consistent with other 
reports.  
In describing the prospects for improving STS care, several challenges remain important to 
emphasize. Most importantly, with an incidence rate of approximately 3 cases per 100,000 
inhabitants (European Standardized Rate),(1) STS represent a group of uncommon tumors 
that show diverse presentations. A general practitioner in the Netherlands encounters on 
average one STS patient every twenty years and a general or orthopedic surgeon one in every 
four years. At the same time, as mentioned, benign soft-tissue tumors are over 100 times as 
common as STS.(34, 35) Misdiagnosis and inadequate treatment are likely to occur. 
It is clear that optimal STS care requires extensive, multidisciplinary expertise and well-
organized care processes, and studies have confirmed benefit for management in sarcoma 
centers, or in hospitals working within specialized, dedicated STS networks.(36-39)  
All in all, improvements in STS care may be achieved by having management primarily 
carried out in reference centers for sarcomas. Within reference networks, centers may share 
Soft tissue sarcoma care in the Netherlands 
 10 
their multidisciplinary expertise and treat large numbers of patients. In this setting, 
centralized referral should be pursued as early as possible, preferably at the time of the 
clinical diagnosis of a suspected sarcoma. In practice, referral of all patients with a lesion 
likely to be a sarcoma would be recommended. This would mean referring all patients with 
an unexplained deep mass of soft tissues, or with a superﬁcial lesion of soft tissues having a 
diameter of >5 cm.(17) Although more centralized management may come with the cost of 
large numbers of patients being redirected to centers for benign abnormalities, potentially 
causing delayed treatment of those with proven STS,(40) some have reported encouraging 
outcomes for more stringent referral patterns.(41) In the Netherlands, national referral 
guidelines are already well-established for bone sarcoma. 
While specific criteria for reference centers may vary from country to country, centralizing 
STS care should be based, among others, on the availability of state-of-the-art facilities for 
STS diagnostics and treatment, multidisciplinary expertise (employed in weekly tumor 
boards discussing new patients, for instance), and larger volumes of patients. Quality of STS 
care delivered should be monitored, and outcomes reported on a regular basis. Also, centers 
are involved in ongoing clinical trials, for which patients’ enrollment is common. 
In the Netherlands, centralizing STS care in five dedicated sarcoma centers, in analogy with 
the four national bone sarcoma centers, may enhance the development and implementation of 
new diagnostics (e.g. imaging technologies and improved STS subtyping according to tumors’ 
molecular make-up) and therapeutic strategies (introduction of new combined, pathway 
driven treatment modalities). Moreover, restricting the number of centers should facilitate a 
nationwide pathology review and reporting standard, and foster focused research initiatives 
on the mentioned themes. Hence, centralization may prove most beneficial for establishing 
disease-orientated sarcoma care, including participation in trials, which eventually should 
lead not only to more favorable clinical outcomes, but also to more efficient and cost-
effective STS.(42) It is time for integrated sarcoma care, in the Netherlands and in 
Europe.(43) 
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Table 1 General characteristics and resection rates for adult patients (≥18 years) diagnosed 
with a soft tissue sarcoma (STS) in the Netherlands during the time period 2006–2011 
 
Total 
(n=3,317) 
 
Resection 
(n=2,698; 81.3%)  
R1 resection 
(n=393; 20.4%)* 
 n %  n % p  n % p 
Sex      p=0.10    p=0.20 
Male 1,830 55.1%  1,507 55.9%   205 52.2%  
Female 1,487 44.9%  1,191 44.1%   188 47.8%  
Age at diagnosis, y      p<0.00    p<0.00 
18–49 794 23.9%  691 25.6%   85 21.6%  
50–64 965 29.1%  807 29.9%   99 25.2%  
65–79 1,036 31.2%  823 30.5%   130 33.1%  
≥80 522 15.7%  377 14.0%   79 20.1%  
Median (interquartile 
range) 
63 (50–75)  62 (49–74)   66 (52–77)  
Primary tumor site      p<0.00    p<0.00 
Head and neck 354 10.7%  293 10.9%   44 11.2%  
Trunk 1,192 35.9%  856 31.7%   98 24.9%  
(Retro)peritoneum 227 6.8%  169 6.3%   39 9.9%  
Extremity 1,544 46.6%  1,380 51.2%   212 53.9%  
Upper 431 13.0%  392 14.5%   75 19.1%  
Lower 1,113 33.6%  988 36.6%   137 34.9%  
Tumor grade      p<0.00    p=0.95 
Low grade 566 17.1%  528 19.6%   76 19.3%  
High grade 1,838 55.4%  1,526 56.6%   246 62.6%  
Unknown 913 27.5%  644 23.9%   71 18.1%  
Tumor size**      p<0.00    p<0.00 
≤5 cm 933 32.4%  892 38.2%   120 30.5%  
>5 cm 1,752 60.9%  1,334 57.2%   262 66.7%  
Unknown 193 6.7%  107 4.6%   11 2.8%  
Depth of tumor**      p<0.00    p=0.01 
Superficial 1,437 45.7%  1,355 52.5%   179 45.6%  
Deep 1,348 42.9%  996 38.6%   178 45.3%  
Unknown 360 11.5%  232 9.0%   36 9.2%  
Stage      p<0.00    - 
Localized disease 2,838 85.6%  2,525 93.6%   393 100.0%  
Distant metastases 479 14.4%  173 6.4%   - -  
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* excluding R2 resections, cases for which residual disease could not be determined (RX) and metastatic disease 
** excluding cases for which extent of disease (EOD) stage could be determine 
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Table 2 STS subtypes diagnosed in adult patients (≥18 years) in the Netherlands during the 
time period 2006–2011 
Sarcoma subtype (WHO 2002) Total   
Median 
age 
(interquar
tile range) 
  
Male / 
female 
  n %   y   % / % 
liposarcoma 668 20,1 
 
60 (49–71) 
 
59,6 / 40,4 
well differentiated liposarcoma 256 7,7 
 
61 (53–71) 
 
58,6 / 41,4 
myxoid liposarcoma 158 4,8 
 
46 (37–60) 
 
57,0 / 43,0 
round cell liposarcoma 10 0,3 
 
47 (44–52) 
 
90,0 / 10,0 
pleomorphic liposarcoma 48 1,4 
 
67 (60–76) 
 
58,3 / 41,7 
dedifferentiated liposarcoma 150 4,5 
 
65 (56–73) 
 
59,3 / 40,7 
mixed-type liposarcoma 8 0,2 
 
65 (48–74) 
 
75,0 / 25,0 
liposarcoma nos 38 1,1 
 
70 (57–79) 
 
68,4 / 31,6 
fibrosarcoma 381 11,5 
 
65 (55–76) 
 
55,6 / 44,4 
well differentiated fibrosarcoma 83 2,5 
 
60 (48–74) 
 
45,8 / 54,2 
conventional fibrosarcoma 66 2,0 
 
65 (57–77) 
 
56,1 / 43,9 
poorly differentiated fibrosarcoma 135 4,1 
 
68 (61–80) 
 
56,3 / 43,7 
fibrosarcoma nos 97 2,9 
 
64 (48–75) 
 
62,9 / 37,1 
leiomyosarcoma 701 21,1 
 
64 (53–75) 
 
56,5 / 43,5 
well differentiated leiomyosarcoma 148 4,5 
 
61 (50–73) 
 
58,8 / 41,2 
conventional leiomyosarcoma 180 5,4 
 
64 (53–75) 
 
55,0 / 45,0 
poorly differentiated / pleiomorphic / epithlioid 
leiomyosarcoma 
137 4,1 
 
64 (57–75) 
 
51,8 / 48,2 
leiomyosarcoma nos 236 7,1 
 
67 (54–76) 
 
58,9 / 41,1 
rhabdomyosarcoma 91 2,7 
 
56 (42–65) 
 
67,0 / 33,0 
(embryonal) rhabdomyosarcoma 40 1,2 
 
53 (35–64) 
 
75,0 / 25,0 
alveolar rhabdomyosarcoma 13 0,4 
 
26 (21–42) 
 
53,8 / 46,2 
pleomorphic rhabdomyosarcoma 38 1,1 
 
63 (54–71) 
 
63,2 / 36,8 
epithelioid haemangioendothelioma 15 0,5 
 
48 (36–59) 
 
40,0 / 60,0 
angiosarcoma 199 6,0 
 
68 (61–79) 
 
33,2 / 66,8 
synovial sarcoma 111 3,3 
 
45 (32–59) 
 
55,0 / 45,0 
malignant peripheral nerve sheath tumor (MPNST) 165 5,0 
 
50 (36–67) 
 
55,8 / 44,2 
malignant fibrous histiocytoma (MFH) / pleomorphic 
undifferentiated sarcoma (PUS) 
338 10,2 
 
71 (60–81) 
 
54,7 / 45,3 
other sarcoma 648 19,5 
 
64 (49–76) 
 
54,5 / 45,5 
total 3,317 100,0   63 (50–75)   55,2 / 44,8 
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Figure 1 Distribution of patients over hospitals performing STS surgery during the time 
period 2006–2011 
 
 
 
  
0%
20%
40%
60%
80%
100%
0% 20% 40% 60% 80% 100%
P
ro
p
o
rt
io
n
 o
f 
S
T
S
 p
at
ie
n
ts
 
Proportion of hospitals performing STS surgery 
90% of patients 
75% 
50% 
sarcoma research center 
Soft tissue sarcoma care in the Netherlands 
 18 
Figure 2 Trends over time according to hospital volume and hospital type with respect to 
STS surgery 
 
A. Hospital volume* 
 
B. Academic versus general hospitals 
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C. Sarcoma research center* 
 
* statistically significant (p<0.01)
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Table 3 Variation in clinical indicators by hospital volume and hospital type, with estimations based on imputed data and adjusted for case mix 
factors (patients’ age, primary tumor site, sarcoma grade, size, and depth, and resection status if relevant)  
 
Overall 
 Hospital volume 
(≥10 cases versus <10 cases) 
 
Hospital type 
(academic versus general)  
Sarcoma research center 
(yes versus no) 
  Crude Adjusted  Crude Adjusted  Crude Adjusted 
 %  OR OR 95%CI  OR OR 95%CI  OR OR 95%CI 
Pathology report: subtype**              
Unknown subtype 20.4%  1.05 1.08 (0.89–1.32)  0.93 0.99 (0.81–1.21)  1.06 1.16 (0.93–1.45) 
Pathology report: grade**              
Unknown grade 27.5%  0.85 0.96 (0.80–1.13)  0.53* 0.65* (0.53–0.78)  0.54* 0.68* (0.54–0.84) 
Unknown grade 
liposarcoma, fibrosarcoma, leiomyosarcoma, 
excluding well-differentiated liposarcoma 
24.0% 
 
0.83 0.93 (0.71–1.21)  0.56* 0.65* (0.48–0.88)  0.56* 0.65* (0.46–0.93) 
Residual disease following resection              
Unknown resection status** 24.0%  0.87 0.99 (0.81–1.21)  0.56* 0.70* (0.56–0.87)  0.58* 0.73* (0.57–0.94) 
Microscopic residual disease (R1) 
excluding M1 and (retro)peritoneal tumors 
20.0% 
 
1.23 1.22 (0.95–1.57)  1.41* 1.41* (1.09–1.82)  1.53* 1.56* (1.22–2.00) 
Macroscopic residual disease (R2) 
excluding M1 and (retro)peritoneal tumors 
3.0% 
 
1.00 0.67 (0.37–1.21)  1.24 0.76 (0.42–1.38)  1.23 0.94 (0.52–1.69) 
Possible ‘whoops’ resection              
Resection of deep or large tumors (>5 cm) 
without prior histopathologic confirmation 
32.0% 
 
0.19* 0.19* (0.15–0.24)  0.18* 0.18* (0.14–0.23)  0.22* 0.20* (0.16–0.26) 
Radiotherapy 
excluding M1 and (retro)peritoneal tumors 
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No radiotherapy 
neoadjuvant or adjuvant 
58.1% 
 
0.39* 0.56* (0.47–0.68)  0.36* 0.53* (0.43–0.65)  0.38* 0.53* (0.43–0.64) 
No adjuvant radiotherapy 
following R1 resection 
52.6% 
 
0.43* 0.50* (0.31–0.80)  0.46* 0.56* (0.35–0.90)  0.42* 0.47* (0.29–0.74) 
   Crude Adjusted***  Crude Adjusted***  Crude Adjusted*** 
 %  HR HR 95%CI  HR HR 95%CI  HR HR 95%CI 
Overall survival 
surgically treated patients, excluding low-grade 
and M1 disease 
 
 
           
5-Year postdiagnosis 
 
61.3% 
 
1.12 1.15 (0.99–1.34)  1.15* 1.14 (0.97–1.33)  1.10 1.08 (0.93–1.27) 
* statistically significant (p<0.05) 
** comparison is calculated on the level of pathology laboratory 
*** additionally adjusted for adjuvant treatment
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Supplementary table 1 
Classification of STS based on the International Classification of Diseases for Oncology 
(ICD-O-3) and the World Health Organization (WHO) classification 2002 
Sarcoma subtype (WHO 2002) Morphology code              Grade 
liposarcoma M8850–M8858  
well differentiated liposarcoma M8851 low 
myxoid liposarcoma M8852 low 
round cell liposarcoma M8853 high 
pleomorphic liposarcoma M8854 high 
dedifferentiated liposarcoma M8858 high 
mixed-type liposarcoma M8855 high 
liposarcoma nos M8850 unspecified 
fibrosarcoma M8810–M8825, M9150  
well differentiated fibrosarcoma M8810–M8825, M9150 low 
conventional fibrosarcoma M8810–M8825, M9150 high 
poorly differentiated fibrosarcoma M8810–M8825, M9150 high 
fibrosarcoma nos M8810–M8825, M9150 unspecified 
leiomyosarcoma M8890–M8896  
well differentiated leiomyosarcoma M8890–M8896 low 
conventional leiomyosarcoma M8890–M8896 high 
poorly differentiated leiomyosarcoma M8890–M8896 high 
leiomyosarcoma nos M8890–M8896 unspecified 
rhabdomyosarcoma M8895, M8900–M8902, M8910–M8912, 
M8920–M8921, M8991 
 
(embryonal) rhabdomyosarcoma M8895, M8900–M8902, M8910–M8912, 
M8991 
high 
alveolar rhabdomyosarcoma M8902, M8920–M8921 high 
pleomorphic rhabdomyosarcoma M8901 high 
epithelioid haemangioendothelioma M9130, M9133 low–high 
angiosarcoma M9120, M9170 high** 
synovial sarcoma M9040–M 9043 high 
MPNST M9540–9571 high** 
MFH/undifferentiated pleiomorphic sarcoma M8830–M8831, M9251–M9252 high 
other sarcoma types various* various 
* These include: glomus tumor (M8711), PNET/extraskeletal Ewing tumor (M9260, M9364, M9365), clear cell 
sarcoma of soft tissue (M9044), extra-renal rhabdoid tumor (M8963) and sarcoma nos, including malignant 
mesenchymoma (M8990). 
** Grades were assigned according to the WHO classification 2013 
 
